CytoSorbents Board Approves Reverse Split to Regain Nasdaq Compliance
CTSO sits 21% above its 52-week low of $0.3 on elevated volume (25× avg).
Summary
CytoSorbents announced a reverse stock split, following shareholder approval on August 13. The board has selected a ratio within the authorized 1-for-5 to 1-for-20 range, though the exact ratio is not specified in the headline. This action is aimed at boosting the share price to meet Nasdaq's minimum bid requirement and avoid delisting. The company faces a going concern warning and a $9.5M H1 net loss, making the split a critical step to maintain its listing. The split will reduce the number of outstanding shares, potentially increasing the stock price proportionally, but does not change the company's fundamental value. Investors should watch for the effective date and the exact ratio, which will determine the post-split share count and price.
At the time of this announcement, CTSO was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.1M. The 52-week trading range was $0.30 to $1.04. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.